Service Corporation International's Wide Moat and $15.4B Preneed Backlog Present a Value Play Amid Valuation Reset

The core of any value investment is a durable competitive advantage, or "moat," that can protect profits and enable long-term compounding. Service Corporation International (SCI) possesses one of the widest moats in the consumer staples sector, built on the inescapable nature of its service. The company is the undisputed leader, holding an estimated 15 to 16 percent share of a fragmented North American deathcare market, a position that makes it nearly four times larger than its nearest publicly traded rival. This scale is not just a number; it translates into a formidable operational and financial barrier to entry.

That scale manifests in a vast, integrated network of ~1,500 funeral homes and ~490 cemeteries. This physical footprint, combined with centralized operations for procurement and back-office functions, creates powerful economies of scale. It allows SCI to negotiate favorable terms with suppliers, maintain consistent service standards, and fund the capital-intensive perpetual care endowments required for cemetery operations. This network effect is a key reason why the industry remains so fragmented-while roughly 80% of the market is still held by independent, family-owned operators, SCI's sheer size and resources make it difficult for them to compete on a national scale, especially in urban and suburban areas where the company has the strongest presence.

The most critical durable asset, however, is the company's record preneed backlog of $15.4 billion. This is not just a sales pipeline; it is a long-term revenue contract that provides exceptional visibility. These are pre-paid agreements for future services, which SCI invests in trust funds, generating recurring investment income. This backlog acts as a massive, built-in moat, locking in future cash flows and reducing the volatility of the top line. It is a tangible asset that directly contributes to intrinsic value, as it represents a stream of earnings that will be realized over many years.

Viewed through a value lens, the business model is compelling. It operates in a market with inelastic demand driven by a steady demographic tailwind. While cremation rates are rising and consumer preferences are shifting, the fundamental need for deathcare services persists. SCI's scale and diversified offerings-spanning traditional funerals, cremations, cemetery sales, and merchandise-allow it to adapt while maintaining high profitability. The company's adjusted EBITDA margin near 30 percent is well above the industry average, a clear testament to its pricing power and cost advantages. For a patient investor, this combination of a wide moat, a durable asset in the preneed backlog, and a business with pricing power in a necessary service creates a setup for steady compounding.

Financial Health and the 2026 Transition

The company's financial performance in 2025 was solid, demonstrating the resilience of its underlying business. Full-year GAAP diluted earnings per share grew 8% to $3.80. A key driver was the 11% growth in comparable preneed funeral sales production during the quarter, which provides a critical buffer for future revenue. The business also generated robust cash flow, with adjusted operating cash flow of $966 million for the year, enabling disciplined capital deployment and shareholder returns.

Yet the recent stock reaction points to a shift in the investment thesis. Despite meeting the earnings beat, shares pulled back 5.1% over the last 7 days and 7.5% over ten days following the fourth-quarter report. This "sell the news" move was triggered by a slight revenue miss and, more importantly, a cautious outlook that signals a transition from rapid growth to cost management. The market had priced in a growth narrative, but management's guidance now sets a lower bar.

For 2026, the outlook is one of operational stability. Management expects flat volumes and points to higher general and administrative expenses as a new, ongoing cost headwind. The company's modest EPS growth target of 5% to 13% reflects this shift, assuming cost containment measures will offset the pressure. CEO Tom Ryan also indicated that funeral service volumes are unlikely to stabilize until 2027-2029, meaning the volume declines that affected Q4 revenue are expected to persist for several years. This extended period of flat or declining volumes limits top-line growth opportunities and forces a focus on pricing and efficiency.

From a value perspective, this transition is a reality check. The stock's pullback has removed some of the growth premium, but the new guidance introduces a longer runway of operational challenges. The key question for investors is whether the company's wide moat and preneed backlog can generate sufficient cash flow to support its capital commitments and shareholder returns while navigating these headwinds. The financial health remains strong, but the path to future earnings growth has become more defined and less certain.

Valuation: Margin of Safety and Intrinsic Value

The recent pullback has reset the valuation, but the question for a value investor is whether the current price offers a sufficient margin of safety. The trailing P/E of approximately 21.7 is a premium to both the company's own historical average and to its closest peer, Carriage Services, which trades at a P/E of about 12. This suggests the market is still pricing in some growth, even as the company's own guidance points to a period of flat volumes and higher costs. For a business with a wide moat, this premium is not unusual, but it also means the stock is not trading at a classic "value" discount.

A more telling analysis comes from a discounted cash flow model. This approach, which projects future cash flows and discounts them back to today, suggests the stock is undervalued by approximately 24.7%. The model arrives at an intrinsic value of about $100 per share, implying a significant margin of safety if the company can successfully navigate the near-term transition. This gap between price and estimated intrinsic value is the core of the investment case. It represents the buffer that a value investor seeks, where the market's current pessimism may be overstating the risks of the 2026 outlook.

The key valuation question, then, is whether the current price adequately discounts the risk of flat volumes and higher costs. The DCF analysis assumes the company can manage through these headwinds and eventually unlock its cash flow potential. The model's 24.7% undervaluation implies it does. The risk is that the market's caution is justified, and the path to compounding is longer and more arduous than the model assumes. The stock's recent volatility, including a 5.1% drop over the last 7 days following the earnings report, shows how sensitive it is to any sign of operational weakness.

For a patient investor, the setup hinges on the durability of the moat. The $15.4 billion preneed backlog provides a long-term revenue anchor, and the company's scale offers pricing power. If SCI can contain costs and stabilize its sales force, the cash flow trajectory projected by the DCF may still be achievable. In that case, the current price offers a margin of safety. If not, the premium P/E and the extended period of flat volumes could pressure the stock further. The value proposition is not in the near-term earnings beat, but in the long-term compounding potential of a durable business, priced at a discount to its estimated intrinsic worth.

Catalysts, Risks, and the Patient Investor's Path

For the patient investor, the current setup is one of waiting for tangible progress. The stock's recent pullback has reset expectations, but the investment thesis now hinges on the company's ability to execute its new, more conservative plan. The primary catalyst is the upcoming April 29, 2026 earnings call. This will be the first opportunity to see if management's announced cost containment measures are effectively offsetting the projected rise in general and administrative expenses. Investors will scrutinize the quarterly results for signs of margin stability and any shift in the volume outlook. A clean beat on adjusted earnings, coupled with clear evidence of cost discipline, could begin to rebuild confidence and validate the discounted cash flow model's intrinsic value estimate.

A significant risk, however, is not internal but regulatory. The company faces potential changes to the Federal Trade Commission's Funeral Rule, which governs how funeral providers disclose prices and services. Any material revision to this rule could impact service delivery models and, more critically, the company's pricing power-a key component of its wide moat. While the rule is a long-term overhang, not an immediate threat, it represents a structural vulnerability that could erode profitability if implemented in a way that increases transparency or competition.

In the meantime, leading indicators will provide a clearer picture of the business's health and the durability of its moat. The trajectory of comparable preneed sales production is paramount. Consistent growth here, like the 11% increase in Q4 2025, signals that the company is successfully converting future demand into locked-in revenue, reinforcing the $15.4 billion backlog. Equally important is the growth of cemetery trust funds, which are invested to cover future perpetual care costs. Growth in these funds is a direct indicator of future earnings visibility and the financial strength of the backlog moat. Monitoring these metrics quarter by quarter will show whether the company is building its long-term value, even as it navigates the near-term cost headwinds.

The path forward, therefore, is one of patience and disciplined monitoring. The stock's volatility reflects the market's uncertainty about the 2026 transition. For a value investor, the margin of safety exists in the intrinsic value gap, but it will only be realized if the company demonstrates it can manage through its challenges. The April earnings call is the first checkpoint; the preneed and trust fund data are the ongoing scorecard. The patient investor's role is to watch for the evidence that the durable business model is still compounding, even if the pace slows.